190 related articles for article (PubMed ID: 30083881)
21. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.
Kawasaki K; Fujii M; Sato T
Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29590641
[TBL] [Abstract][Full Text] [Related]
22. Spatial profiling reveals tissue-specific neuro-immune interactions in gastroenteropancreatic neuroendocrine tumors.
Duan S; Sawyer TW; Witten BL; Song H; Else T; Merchant JL
J Pathol; 2024 Mar; 262(3):362-376. PubMed ID: 38229586
[TBL] [Abstract][Full Text] [Related]
23. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
[TBL] [Abstract][Full Text] [Related]
24. DNA methylation profiles distinguish different subtypes of gastroenteropancreatic neuroendocrine tumors.
How-Kit A; Dejeux E; Dousset B; Renault V; Baudry M; Terris B; Tost J
Epigenomics; 2015; 7(8):1245-58. PubMed ID: 26360914
[TBL] [Abstract][Full Text] [Related]
25. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
[TBL] [Abstract][Full Text] [Related]
26. Somatic and germline mutations in NETs: Implications for their diagnosis and management.
Minnetti M; Grossman A
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):115-27. PubMed ID: 26971848
[TBL] [Abstract][Full Text] [Related]
27. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.
Barrea L; Muscogiuri G; Modica R; Altieri B; Pugliese G; Minotta R; Faggiano A; Colao A; Savastano S
Front Endocrinol (Lausanne); 2021; 12():649496. PubMed ID: 33815296
[TBL] [Abstract][Full Text] [Related]
28. A novel MEN1 frameshift germline mutation in two Italian monozygotic twins.
Concolino P; Rossodivita A; Carrozza C; Raffaelli M; Lombardi CP; Rigante D; Pitocco D; Stabile A; Bellantone R; Zuppi C; Capoluongo E
Clin Chem Lab Med; 2008; 46(6):824-6. PubMed ID: 18601604
[TBL] [Abstract][Full Text] [Related]
29. Distinct clinical phenotypes in a family with a novel truncating MEN1 frameshift mutation.
Welsch C; Flügel AK; Rondot S; Schulze E; Sircar I; Nußbaumer J; Bojunga J
BMC Endocr Disord; 2022 Mar; 22(1):64. PubMed ID: 35287658
[TBL] [Abstract][Full Text] [Related]
30. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
31. Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors.
Kim HS; Lee HS; Nam KH; Choi J; Kim WH
Anticancer Res; 2015 Jun; 35(6):3501-10. PubMed ID: 26026117
[TBL] [Abstract][Full Text] [Related]
32. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing.
Panarelli N; Tyryshkin K; Wong JJM; Majewski A; Yang X; Scognamiglio T; Kim MK; Bogardus K; Tuschl T; Chen YT; Renwick N
Endocr Relat Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 30021866
[TBL] [Abstract][Full Text] [Related]
33. GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers.
Verbeek WH; Korse CM; Tesselaar ME
Eur J Endocrinol; 2016 Jan; 174(1):R1-7. PubMed ID: 26162406
[TBL] [Abstract][Full Text] [Related]
34. Glutaminases in slowly proliferating gastroenteropancreatic neuroendocrine neoplasms/tumors (GEP-NETs): Selective overexpression of mRNA coding for the KGA isoform.
Szeliga M; Ćwikła J; Obara-Michlewska M; Cichocki A; Albrecht J
Exp Mol Pathol; 2016 Feb; 100(1):74-8. PubMed ID: 26581715
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1).
Gaztambide S; Vazquez F; Castaño L
Minerva Endocrinol; 2013 Mar; 38(1):17-28. PubMed ID: 23435440
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG).
van Beek DJ; Nell S; Pieterman CRC; de Herder WW; van de Ven AC; Dekkers OM; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
J Surg Oncol; 2019 Nov; 120(6):966-975. PubMed ID: 31401809
[TBL] [Abstract][Full Text] [Related]
37. Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.
Khan MS; Walter T; Buchanan-Hughes A; Worthington E; Keeber L; Feuilly M; Grande E
World J Gastroenterol; 2020 Aug; 26(30):4537-4556. PubMed ID: 32874063
[TBL] [Abstract][Full Text] [Related]
38. Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India.
Goroshi M; Bandgar T; Lila AR; Jadhav SS; Khare S; Shrikhande SV; Uchino S; Dalvi AN; Shah NS
Fam Cancer; 2016 Oct; 15(4):617-24. PubMed ID: 26905068
[TBL] [Abstract][Full Text] [Related]
39. Novel mutations in the MEN1 gene in subjects with multiple endocrine neoplasia-1.
Jap TS; Chiu CY; Won JG; Wu YC; Chen HS
Clin Endocrinol (Oxf); 2005 Mar; 62(3):336-42. PubMed ID: 15730416
[TBL] [Abstract][Full Text] [Related]
40. Signaling networks and the feasibility of computational analysis in gastroenteropancreatic neuroendocrine tumors.
Chen P; Wang Q; Xie J; Kwok HF
Semin Cancer Biol; 2019 Oct; 58():80-89. PubMed ID: 31054326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]